Literature DB >> 24535377

Ivabradine therapy to unmask heart rate-independent effects of β-blockers on pulse wave reflections.

Ulrich Fischer-Rasokat1, Jörg Honold, Denise Lochmann, Christoph Liebetrau, Jürgen Leick, Christian Hamm, Stephan Fichtlscherer, Helge Möllmann, Ioakim Spyridopoulos.   

Abstract

BACKGROUND: Prior studies suggest that β-blockers lead to increased pulse wave reflections, thereby negating the blood pressure lowering effects on cardiovascular mortality. Parts of these effects may be induced by the heart rate reduction under β-blockade. The aim of this study was to unmask heart rate-independent effects of β-blockade on pulse wave reflections by switching therapy from β-blockers to ivabradine, an I f channel inhibitor without impact on systemic hemodynamics.
METHODS: 14 male patients (age 61 ± 3 years, LVEF 62 ± 1 %) with arterial hypertension and coronary artery disease (CAD) under chronic β-blocker therapy at moderate dosage and additional renin-angiotensin system-blocking therapy were included. We determined radial augmentation index (rAI) by radial applanation tonometry in patients under β-blockade both at rest and during early recovery after exercise. β-Blockers were then replaced by ivabradine. Six weeks later, patients were re-tested at rest and after exercise under ivabradine therapy.
RESULTS: Mean heart rate (68 ± 3 vs. 63 ± 3 bpm; p = ns) and resting mean arterial pressure (98 ± 2 vs. 98 ± 2 mmHg; p = ns) were not different between β-blocker or ivabradine therapy, respectively. The rAI remained unchanged after switching therapy from β-blocker to ivabradine (86 ± 2 vs. 84 ± 4 %; p = ns). Post exercise, the rAI revealed an identical decrease in both groups (-7.2 ± 2.4 vs. -5.4 ± 2.5 %, p = ns). The increase in heart rate between resting conditions and early recovery post exercise was inversely correlated with the decrease of rAI under β-blockade (r = -0.70; p < 0.01) and showed a trend towards correlation under ivabradine (r = -0.52; p = 0.07).
CONCLUSION: In men at the age of 60 years and CAD, β-blockade does not exert heart rate-independent, pleiotropic effects on peripheral pulse wave reflections, both at rest or after exercise. Our results fit well within recent studies, demonstrating the fundamental influence of heart rate on rAI.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24535377     DOI: 10.1007/s00392-014-0679-1

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  48 in total

1.  Effect of bisoprolol on blood pressure and arterial hemodynamics in systemic hypertension.

Authors:  R G Asmar; J C Kerihuel; X J Girerd; M E Safar
Journal:  Am J Cardiol       Date:  1991-07-01       Impact factor: 2.778

Review 2.  Cardiovascular protection using beta-blockers: a critical review of the evidence.

Authors:  Sripal Bangalore; Franz H Messerli; John B Kostis; Carl J Pepine
Journal:  J Am Coll Cardiol       Date:  2007-07-30       Impact factor: 24.094

3.  The 2012 ESC Guidelines on Heart Failure.

Authors:  Jennifer Taylor
Journal:  Eur Heart J       Date:  2012-07       Impact factor: 29.983

4.  The effects of acute beta-adrenergic blockade on aortic wave reflection in postmenopausal women.

Authors:  Darren P Casey; Timothy B Curry; Nisha Charkoudian; Michael J Joyner; Emma C Hart
Journal:  Am J Hypertens       Date:  2013-01-11       Impact factor: 2.689

5.  Acute β-adrenergic blockade increases aortic wave reflection in young men and women: differing mechanisms between sexes.

Authors:  Darren P Casey; Timothy B Curry; Michael J Joyner; Nisha Charkoudian; Emma C Hart
Journal:  Hypertension       Date:  2011-11-21       Impact factor: 10.190

6.  Heart rate reduction by ivabradine reduces diastolic dysfunction and cardiac fibrosis.

Authors:  David Busseuil; Yanfen Shi; Mélanie Mecteau; Geneviève Brand; Marc-Antoine Gillis; Eric Thorin; Caroline Asselin; Philippe Roméo; Tack Ki Leung; Jean-Gilles Latour; Christine Des Rosiers; Muriel Bouly; Eric Rhéaume; Jean-Claude Tardif
Journal:  Cardiology       Date:  2011-01-08       Impact factor: 1.869

7.  β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease.

Authors:  Sripal Bangalore; Gabriel Steg; Prakash Deedwania; Kevin Crowley; Kim A Eagle; Shinya Goto; E Magnus Ohman; Christopher P Cannon; Sidney C Smith; Uwe Zeymer; Elaine B Hoffman; Franz H Messerli; Deepak L Bhatt
Journal:  JAMA       Date:  2012-10-03       Impact factor: 56.272

8.  Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice.

Authors:  A Drouin; M-E Gendron; E Thorin; M-A Gillis; F Mahlberg-Gaudin; J-C Tardif
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

9.  Altered arterial stiffness and subendocardial viability ratio in young healthy light smokers after acute exercise.

Authors:  Robert J Doonan; Patrick Scheffler; Alice Yu; Giordano Egiziano; Andrew Mutter; Simon Bacon; Franco Carli; Marios E Daskalopoulos; Stella S Daskalopoulou
Journal:  PLoS One       Date:  2011-10-10       Impact factor: 3.240

10.  2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).

Authors:  Giuseppe Mancia; Robert Fagard; Krzysztof Narkiewicz; Josep Redon; Alberto Zanchetti; Michael Böhm; Thierry Christiaens; Renata Cifkova; Guy De Backer; Anna Dominiczak; Maurizio Galderisi; Diederick E Grobbee; Tiny Jaarsma; Paulus Kirchhof; Sverre E Kjeldsen; Stéphane Laurent; Athanasios J Manolis; Peter M Nilsson; Luis Miguel Ruilope; Roland E Schmieder; Per Anton Sirnes; Peter Sleight; Margus Viigimaa; Bernard Waeber; Faiez Zannad; Josep Redon; Anna Dominiczak; Krzysztof Narkiewicz; Peter M Nilsson; Michel Burnier; Margus Viigimaa; Ettore Ambrosioni; Mark Caufield; Antonio Coca; Michael Hecht Olsen; Roland E Schmieder; Costas Tsioufis; Philippe van de Borne; Jose Luis Zamorano; Stephan Achenbach; Helmut Baumgartner; Jeroen J Bax; Héctor Bueno; Veronica Dean; Christi Deaton; Cetin Erol; Robert Fagard; Roberto Ferrari; David Hasdai; Arno W Hoes; Paulus Kirchhof; Juhani Knuuti; Philippe Kolh; Patrizio Lancellotti; Ales Linhart; Petros Nihoyannopoulos; Massimo F Piepoli; Piotr Ponikowski; Per Anton Sirnes; Juan Luis Tamargo; Michal Tendera; Adam Torbicki; William Wijns; Stephan Windecker; Denis L Clement; Antonio Coca; Thierry C Gillebert; Michal Tendera; Enrico Agabiti Rosei; Ettore Ambrosioni; Stefan D Anker; Johann Bauersachs; Jana Brguljan Hitij; Mark Caulfield; Marc De Buyzere; Sabina De Geest; Geneviève Anne Derumeaux; Serap Erdine; Csaba Farsang; Christian Funck-Brentano; Vjekoslav Gerc; Giuseppe Germano; Stephan Gielen; Herman Haller; Arno W Hoes; Jens Jordan; Thomas Kahan; Michel Komajda; Dragan Lovic; Heiko Mahrholdt; Michael Hecht Olsen; Jan Ostergren; Gianfranco Parati; Joep Perk; Jorge Polonia; Bogdan A Popescu; Zeljko Reiner; Lars Rydén; Yuriy Sirenko; Alice Stanton; Harry Struijker-Boudier; Costas Tsioufis; Philippe van de Borne; Charalambos Vlachopoulos; Massimo Volpe; David A Wood
Journal:  Eur Heart J       Date:  2013-06-14       Impact factor: 29.983

View more
  5 in total

1.  β-Blockers and ivabradine differentially affect cardiopulmonary function and left ventricular filling index.

Authors:  Ulrich Fischer-Rasokat; Jörg Honold; Denise Lochmann; Sebastian Wolter; Christoph Liebetrau; Stephan Fichtlscherer; Helge Möllmann; Ioakim Spyridopoulos; Christian W Hamm
Journal:  Clin Res Cardiol       Date:  2015-12-19       Impact factor: 5.460

2.  Radial artery applanation tonometry for continuous noninvasive arterial blood pressure monitoring in the cardiac intensive care unit.

Authors:  Nicolas Langwieser; Luisa Prechtl; Agnes S Meidert; Alexander Hapfelmeier; Christian Bradaric; Tareq Ibrahim; Karl-Ludwig Laugwitz; Roland M Schmid; Julia Y Wagner; Bernd Saugel
Journal:  Clin Res Cardiol       Date:  2015-01-25       Impact factor: 5.460

3.  Heart Rate reduction by IVabradine for improvement of ENDothELial function in patients with coronary artery disease: the RIVENDEL study.

Authors:  Fabio Mangiacapra; Iginio Colaiori; Elisabetta Ricottini; Francesco Balducci; Antonio Creta; Chiara Demartini; Giorgio Minotti; Germano Di Sciascio
Journal:  Clin Res Cardiol       Date:  2016-08-12       Impact factor: 5.460

4.  Ivabradine and Blood Pressure Reduction: Underlying Pleiotropic Mechanisms and Clinical Implications.

Authors:  Fedor Simko; Tomas Baka
Journal:  Front Cardiovasc Med       Date:  2021-02-10

5.  Atenolol's Inferior Ability to Reduce Central vs Peripheral Blood Pressure Can Be Explained by the Combination of Its Heart Rate-Dependent and Heart Rate-Independent Effects.

Authors:  Tuuli Teeäär; Martin Serg; Kaido Paapstel; Mare Vähi; Jaak Kals; John R Cockcroft; Mihkel Zilmer; Jaan Eha; Priit Kampus
Journal:  Int J Hypertens       Date:  2020-04-26       Impact factor: 2.420

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.